Bristol-Myers Squibb (BMY) Tops Q3 EPS by 30c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at Leerink Partners
November 4, 2024 6:20 AM ESTLeerink Partners analyst David Risinger raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $55.00 (from $53.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line. We are increasing our PT from $53 (7.5x old 25E EPS of $7.06) to $55 (7.5x new 25E... More
